Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio SwallowFIT sul Morbo di Parkinson

"SwallowFit," un Programma di Esercizio e Studio Clinico Randomizzato Progettato per i Membri del Servizio degli Stati Uniti, Veterani e Famiglie Affetti dal Morbo di Parkinson.

The goal of this clinical trial is to learn if a proactive swallow exercise will help to improve swallow fitness in patients with Parkinson's disease.

The aim of the study is to assess how effective this exercise is and to measure the change in swallowing fitness from the beginning to the end of the study.

Patients who are given the exercise training will be compared to participants who are treated using the usual standard treatment.

Patients will have 6 weeks of twice-weekly SwallowFIT training. Each session will be an hour long.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

SwallowFIT: Subjects will receive 6-weeks of twice weekly SwallowFIT intervention per protocol (1-hour session each visit) from the BAMC speech language Pathologist (study SLP) at BAMC. Completion of the program will include 12 visits. The program is designed from a previous successful pilot trial. It begins with provision of general education on swallowing and swallowing change from the Parkinson's Foundation and Michael J Fox association websites.

Following this the program trains a modified effortful swallow technique at its onset using sEMG to guide the development of better swallow movement form, effort and performance. Once swallowing form is established, the program uses a hierarchy of swallowing tasks involving swallowing food/fluid materials at different complexity levels (swallow specificity) to stimulate and train progressive resistance and leverage variability of coordinated speeded actions.

Clinical Monitoring Only (CMO): This intervention mirrors the experimental intervention in all aspects, but the treatment type applied. CMO intervention reflects current swallow management practice for PD, where physicians monitor clinical function in swallowing and other related symptomology, referring for swallowing treatment only once an obvious issue has been identified.

Tipo di studio

Interventistico

Iscrizione (Stimato)

80

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Texas
      • San Antonio, Texas, Stati Uniti, 78234-6200
        • Brooke Army Medical Center (BAMC)
        • Contatto:
        • Contatto:
          • Alexis Nelson
          • Numero di telefono: 210-916-2203.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 35 anni a 90 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Adult S-VWP between >35-90 years of age
  2. Diagnosis of Idiopathic Parkinson's Disease [IDP] (either or suspected, tremor-predominant or rigid predominant)
  3. Disability level of Hoehn & Yahr stages II-III as indicated in their most recent neurological evaluation
  4. Swallowing concern, confirmed by Modified Unified Parkinson Disease Rating Scale [MDS-UPDRS]-
  5. ADL swallowing item >0, or Mann Assessment of Swallowing scale [MASA] score ≤185.
  6. Able to consume oral nutrition [Functional Oral Intake Score ≤ 6]
  7. Ambulatory
  8. No change of medication for at least 4 weeks before study inclusion

Exclusion Criteria:

  1. Classified as Hoehn and Yahr stages IV
  2. Unable to follow 2 step commands
  3. History of other neurological disease potentially causing dysphagia
  4. Dementia (MMSE<20; Montreal cognitive assessment (MoCA) ≤ 20)
  5. Severe depression (BDI>19)
  6. Severe dyskinesia of head and neck (resulting in problems with MBSS recording)
  7. Severe documented Gastrointestinal disease
  8. History of Gastro-esophageal surgery
  9. History of Head or neck cancer with swallowing impairment or surgical intervention
  10. History of breathing disorders or diseases (e.g., Asthma, chronic obstructive pulmonary disease (COPD) requiring assistive breathing support.
  11. Untreated hypertension
  12. Heart disease requiring restricted activity and medical intervention
  13. Speech therapy intervention for swallowing within the past three months
  14. Women who are pregnant, nursing, or who plan to become pregnant during the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: SwallowFit Intervention

Subjects randomized to intervention will receive 6-weeks of twice weekly SwallowFIT per protocol (1-hour session each day). The program begins with provision of general education on swallowing and swallowing change from the Parkinson's Foundation and Michael J Fox association websites. Following this the program trains a modified effortful swallow technique at its onset using surface electromyographic (sEMG) biofeedback to guide the development of better swallow movement form, effort and performance. From there it applies a hierarchy of swallowing exercises/tasks involving swallowing food/fluid materials at different complexity levels (swallow specificity) to stimulate and train progressive resistance and leverage variability of coordinated speeded actions.

The SwallowFIT protocol follows an increasing task difficulty (levels on the hierarchy) and motor learning strategy. Progression on the hierarchy is guided and monitored by the occurrence of inefficiency markers in swallow wing (e.g. excessive lingual pumping, swallow hesitation, throat clearing etc.) confirmed from the baseline clinical and video fluoroscopic evaluations.

Altri nomi:
  • Esercizi di deglutizione
Nessun intervento: Clinical Monitoring Only (CMO)

CMO intervention reflects current swallow management practice for PD, where physicians monitor clinical function in swallowing and other related symptomology, referring for swallowing treatment only if an obvious issue has been identified. Subjects randomized to CMO will also receive general education on swallowing and swallow changes from the Parkinson's Foundation and Michael J Fox association websites.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mann Assessment of Swallowing Ability (MASA)
Lasso di tempo: Baseline to 6 months

The MASA score is measured using a 5-point to 10-point rating scale. The total possible score of the MASA is 200 points, and the cutoff value is 177 points. The results of the MASA are interpreted as no abnormality (≥178), mild dysphagia (168-177), moderate dysphagia (139-167), and severe dysphagia (≤138).

Baseline to 6 months
Modified Unified Parkinson Disease Rating Scale (MDS-UPDRS)
Lasso di tempo: Baseline to 6 months

The MDS-UPDRS uses a 0-4 scoring system, with higher scores indicating more severe symptoms. Parts I-III are scored on a 0-4 scale, while Part IV uses "yes" and "no" ratings. The total score range is 0-260, with 0 representing no disability and 260 representing total disability.

Baseline to 6 months
Modified Hoehn and Yahr (HY) Scale
Lasso di tempo: Baseline to 6 months

The Hoehn and Yahr (H&Y) scale is a grading system used to assess the progression and severity of motor symptoms in Parkinson's disease (PD). It ranges from Stage 0 (no signs of disease) to Stage 5 (severe disability, wheelchair or bed bound). Stages 1, 1.5, 2, and 2.5 are considered early stages, while stages 3, 4, and 5 represent later, more advanced stages.

Baseline to 6 months
Montreal Cognitive Assessment (MoCA)
Lasso di tempo: Baseline to 6 months

The Montreal Cognitive Assessment (MoCA) is a cognitive screening tool with a maximum score of 30 points, with a score of 26 or higher generally indicating normal cognitive function. Scores between 18 and 25 may suggest mild cognitive impairment (MCI), while scores below 18 may indicate moderate to severe impairment.

Baseline to 6 months
PD Quality of Life Scale (PDQ-39)
Lasso di tempo: Baseline to 6 months

The PDQ-39 is a questionnaire used to assess the impact of Parkinson's disease on quality of life. It consists of 39 questions, each rated on a 5-point scale from 0 (never) to 4 (always). Scores for the 39 questions are added to obtain a total score.

The scores for the 8 subscales (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and physical discomfort) are obtained by summing the scores for the relevant questions within each subscale.

The total score and subscale scores range from 0 to 100, with higher scores indicating a greater impact of Parkinson's disease on quality of life.

Baseline to 6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Modified Barium Swallowing Impairment Profile, overall impression score (MBSImp OI score)
Lasso di tempo: Baseline to 6 months

In the context of the Modified Barium Swallow Impairment Profile (MBSImP), Overall Impression (OI) scoring is the most common method used to assess swallowing physiology. It involves assigning a score to each of the 17 physiological components based on the most severe impairment observed across different swallowing tasks. These scores range from 0 to 4 depending on the component, and total scores range from 0-68 with higher scores indicating greater impairment.

Baseline to 6 months
Spontaneous Swallowing Frequency (SSF)
Lasso di tempo: Baseline to 6 months

Spontaneous swallowing frequency (SSF) scoring refers to counting the number of times a person swallows without any specific prompting or external stimuli. It's a method used to assess swallowing function, particularly in conditions like dysphagia (difficulty swallowing), and can be a tool for screening and evaluating swallowing problems. A 5-10 minute sampling window is often used to calculate SSF.

Healthy Swallowing:

In healthy individuals, spontaneous swallowing typically occurs at a rate of 1-2 swallows per minute.

Dysphagia:

Patients with dysphagia often have a reduced SSF compared to healthy individuals.

Thresholds:

Some studies have suggested a threshold of 0.40 swallows per minute as a potential indicator of significant dysphagia.

Baseline to 6 months
Penetration Aspiration Scale (PAS)
Lasso di tempo: Baseline to 6 months

The Penetration-Aspiration Scale (PAS) is an 8-point scale used to assess the depth and response to airway invasion during swallowing. It helps clinicians and researchers understand the severity of swallowing dysfunction by categorizing the location of the bolus within the airway and whether it's expelled or not. The scale is used in videofluoroscopic swallowing studies (VFSS) to quantify swallowing event. A score of 1 would indicate no material entered the airway while a score of 8 would indicate the most amount of material aspirated during swallowing.

Baseline to 6 months
Analysis of Swallowing Physiology: Events, Kinematics and Timing (ASPEKT)
Lasso di tempo: Baseline to 6 months

Method of measuring physiologic kinematics and timing for swallowing images retrieved from modified barium swallow (MBSS). It evaluates of 8 key parameters of swallowing taken by frame analysis on open-source NIH, Image J software. Scoring of kinematic swallow movements will be evaluated using the published protocol

Baseline to 6 months
Functional Oral Intake Scale (FOIS)
Lasso di tempo: Baseline to 6 months

The Functional Oral Intake Scale (FOIS) is a 7-point ordinal scale used to assess a patient's ability to swallow and eat safely and efficiently. Scores range from 1 to 7, with higher scores indicating better swallowing function and a greater ability to participate in oral intake.

Baseline to 6 months
Lingual Pressure/movement
Lasso di tempo: Baseline to 6 months

The Lingual Pressure Movement Scale, part of the AIMS (Abnormal Involuntary Movement Scale), assesses the severity of tongue movements. It uses a 0-4 scale, where 0 represents no movement, 1 represents minimal movement (may be extreme normal), 2 represents mild movement, 3 represents moderate movement, and 4 represents severe movement.

Baseline to 6 months
Sydney Swallowing Questionnaire (SSQ)
Lasso di tempo: Baseline to 6 months

The Sydney Swallow Questionnaire (SSQ) is scored by summing the individual scores for each question. It consists of 17 questions, with most questions scored on a visual analog scale (VAS), ranging from 0 to 100 mm. The total possible score is 1700. Higher scores indicate more severe swallowing difficulties.

Baseline to 6 months
Protocol Adherence Measure
Lasso di tempo: Baseline to 6 months

Percentage attendance measured by number of prescribed exercise sessions completed

Baseline to 6 months
Patient Perception of Swallowing (VAS)
Lasso di tempo: Baseline to 6 months

In patient perception of swallowing, a Visual Analogue Scale (VAS) is used to assess a patient's subjective experience of swallowing difficulties. Patients mark a point on a line (typically 100 mm) that represents the severity of their swallowing problem, with 0 indicating no trouble and 100 indicating a total inability to swallow.

Baseline to 6 months
Patient/Caregiver Acceptability/Satisfaction Scale (PA/SS)
Lasso di tempo: Baseline to 6 months

A 5 item scale where each item is scored on a Likert scale from 0-10. Total scores range from 0-50 with a higher score indicating that the SwallowFIT program was more helpful.

Baseline to 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Giselle Carnaby, PhD, MP, The University of Texas Health Science Center at San Antonio

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

30 novembre 2026

Completamento primario (Stimato)

30 marzo 2028

Completamento dello studio (Stimato)

29 giugno 2028

Date di iscrizione allo studio

Primo inviato

12 gennaio 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 gennaio 2026

Primo Inserito (Effettivo)

21 gennaio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • STUDY00001444
  • FY24 HT942524PRPIIRA (Altro numero di sovvenzione/finanziamento: Department of Defense)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The study team will report and publish in a peer-reviewed journal (trials journal) the study protocol and proposed analysis, to provide similar information to the national and international scientific community.

Information provision and awareness-raising will take place during project inception and intensify as results become available.

Study results will be published and displayed on the project webpage following completion of the 6 month follow up of all subjects.

Periodo di condivisione IPD

After the study is complete and unblinded, the study team will submit all remaining scientific data to the data repository, and we will update the study status to "completed" in clinical trials.gov. According to the study timeline, all generated scientific data will approximately coincide with the submission of the results to clinicaltrials.gov and will occur no later than by the end of award. Scientific data included in published manuscripts will be available at the time of publication. According to the proposed project timeline, all generated scientific data will approximately coincide with the submission of the results to clinicaltrials.gov at the end of the award, and full data sharing (via repository) will occur no later than six months after completion of the study or acceptance for publication of the main findings from the final dataset.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .